BeiGene is a relative latecomer to immuno-oncology, and the China-based company’s efforts to bring its first such drug to the U.S. market will have to wait a little longer. An FDA decision for a BeiGene drug for esophageal cancer has been delayed until the agency can complete inspections of the manufacturing facilities for the immunotherapy. The drug, tislelizumab, is […]